Passa al contenuto
Merck

C3160

Complement C5 from human serum

≥90% (SDS-PAGE), >100,000 C5H50 units/mg protein

Sinonimo/i:

C5 human, Complement C5

Slide 1 of 1
Autenticati per visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

0.1 MG

350,00 €

350,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine in blocco

Informazioni su questo articolo

Numero CAS:
80295-53-0
Numero MDL:
MFCD00130840
Codice UNSPSC:
12352202
NACRES:
NA.71

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Origine biologica

human serum

Livello qualitativo

200

Saggio

≥90% (SDS-PAGE)

Stato

solution

Attività specifica

>100,000 C5H50 units/mg protein

Concentrazione

1 mg/mL in PBS, pH 7.2

tecniche

activity assay: suitable

N° accesso UniProt

P01031

Condizioni di spedizione

dry ice

Temperatura di conservazione

−70°C

Informazioni sul gene

human ... C5(727)

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
C1163C2787C2910
Complement C5 from human serum ≥90% (SDS-PAGE), >100,000 C5H50 units/mg protein

Sigma-Aldrich

C3160

Complement C5 from human serum

Complement C5 deficient serum human for complement assays

Sigma-Aldrich

C1163

Complement C5 deficient serum human

Complement C7 from human serum ≥85% (SDS-PAGE), ≥150,000 C7H50 units/mg protein

Sigma-Aldrich

C2787

Complement C7 from human serum

Complement C3 from human serum ≥3000 C3H50 units/mg (using C3 deficient serum)

Sigma-Aldrich

C2910

Complement C3 from human serum

biological source

human serum

biological source

human

biological source

human serum

biological source

human

technique(s)

activity assay: suitable

technique(s)

activity assay: suitable

technique(s)

activity assay: suitable

technique(s)

activity assay: suitable

assay

≥90% (SDS-PAGE)

assay

-

assay

≥85% (SDS-PAGE)

assay

≥85% (SDS-GE)

concentration

1 mg/mL in PBS, pH 7.2

concentration

-

concentration

1 mg/mL in 10 mM sodium phosphate, 150 mM sodium chloride, pH 7.2

concentration

-

form

solution

form

solution

form

solution

form

solution

UniProt accession no.

P01031

UniProt accession no.

P01031

UniProt accession no.

P10643

UniProt accession no.

P01024

Applicazioni

Complement C5 is part of the terminal sequence in the complement pathway. In particular, it is cleaved into C5a and C5b which are responsible for chemotaxis, inflammation, and initiating the formation of the membrane attack complex (MAC). Drugs that inhibit complement C5 have been used in Paroxysmal nocturnal hemoglobinuria (PNH) patients to lessen thrombotic complications by lessening intravascular hemolysis.

Azioni biochim/fisiol

Complement component C5 is processed by convertase enzymes in a cascade modulated in a unique way. The multi-subunit catalytic complex initially shows little activity against C5, but instead cleaves C3. A C3 cleavage product C3b covalently attaches to the complex and shifts its specificity to C5 by a factor of 1000.

Risultati analitici

Functionally active by a sensitive hemolytic assay.

Altre note

View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer

Esclusione di responsabilità

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000497662
0000497662
0000481279
0000481279
SLCR1744

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Peter Hillmen et al.
The New England journal of medicine, 350(6), 552-559 (2004-02-06)
Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement
A M Risitano et al.
Mini reviews in medicinal chemistry, 11(6), 528-535 (2011-05-13)
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evident chronic hemolysis due to the absence of the complement regulators CD55 and CD59 on PNH
The role of complement inhibition in PNH.
Hillmen P.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2008(1), 116-123 (2008)

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica